Evidence map›Paper›PMID 36290779›Full record

ArticleAntioxidants (Basel, Switzerland)2022

A Chlorophyll-Derived Phylloxanthobilin Is a Potent Antioxidant That Modulates Immunometabolism in Human PBMC.

Cornelia A Karg, Lucia Parráková, Dietmar Fuchs, Harald Schennach, Bernhard Kräutler, Simone Moser, Johanna M Gostner

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Modulatory Effects ofAntioxidants (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Cornelia A KargDepartment of Pharmaceutical Biology, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13, 81977 Munich, Germany.
Lucia ParrákováInstitute of Medical Biochemistry, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.
Dietmar FuchsInstitute of Biological Chemistry, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.ORCID 0000-0003-1627-9563
Harald SchennachCentral Institute of Blood Transfusion and Immunology, University Hospital, Anichstr. 35, 6020 Innsbruck, Austria.
Bernhard KräutlerInstitute of Organic Chemistry, Center for Molecular Biosciences, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Simone MoserDepartment of Pharmaceutical Biology, Ludwig-Maximilian University of Munich, Butenandtstr. 5-13, 81977 Munich, Germany.
Johanna M GostnerInstitute of Medical Biochemistry, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.ORCID 0000-0003-1532-5177
Innsbruck Medical University · ATLudwig-Maximilians-Universität München · DEUniversität Innsbruck · ATUniversity Hospital Innsbruck · AT

Funding

Deutsche Forschungsgemeinschaft 448289381FWF Austrian Science Fund P-28522
6 · The paper itself

Abstract

Phyllobilins are natural products derived from the degradation of chlorophyll, which proceeds via a common and strictly controlled pathway in higher plants. The resulting tetrapyrrolic catabolites-the phyllobilins-are ubiquitous in nature; despite their high abundance, there is still a lack of knowledge about their physiological properties. Phyllobilins are part of human nutrition and were shown to be potent antioxidants accounting with interesting physiological properties. Three different naturally occurring types of phyllobilins-a phylloleucobilin, a dioxobilin-type phylloleucobilin and a phylloxanthobilin (PxB)-were compared regarding potential antioxidative properties in a cell-free and in a cell-based antioxidant activity test system, demonstrating the strongest effect for the PxB. Moreover, the PxB was investigated for its capacity to interfere with immunoregulatory metabolic pathways of tryptophan breakdown in human blood peripheral mononuclear cells. A dose-dependent inhibition of tryptophan catabolism to kynurenine was observed, suggesting a suppressive effect on pathways of cellular immune activation. Although the exact mechanisms of immunomodulatory effects are yet unknown, these prominent bioactivities point towards health-relevant effects, which warrant further mechanistic investigations and the assessment of the in vivo extrapolatability of results. Thus, phyllobilins are a still surprisingly unexplored family of natural products that merit further investigation.

Indexed as

kynureninenatural productsphyllobilintetrapyrrolestryptophan

Identifiers

PMID36290779
PMCPMC9599000
OpenAlexW4306836409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.